

WANBURY LIMITED

BSEL Tech Park, B- Wing, 10th Floor, Sector 30A, Opp. Vashi Railway Station, Vashi, Navi Mumbai - 400 705
Unaudited Financial Results for the Quarter ended 31st Dec 2007

(Rupees in Lacs)

| Sr No | Particulars | For the Qtr Ended | For the Qtr Ended | For the Period | For the Period | For the Year |
|--------------------|---|---------------------------|---------------------------|------------------------------------|------------------------------------|----------------------------------|
| | | 31-12-2007 (Unaudited) | 31-12-2006 (Unaudited) | Ended 31-12-2007 (Unaudited) | Ended 31-12-2006 (Unaudited) | Ended 31-03-2007 (Audited) |
| INCOME | | | | | | |
| 1 | Sales/ Income from operations | 5,679.68 | 3,575.97 | 16,572.86 | 9,809.90 | 14,608.02 |
| | Less : Excise Duty | 65.89 | 58.17 | 378.58 | 166.55 | 225.27 |
| | Net Sales/Income from Operation | 5,613.79 | 3,517.80 | 16,194.28 | 9,643.35 | 14,382.75 |
| 2 | Other Income | 257.13 | 316.61 | 776.85 | 757.47 | 880.77 |
| 3 | Total Income (1+2) | 5,870.93 | 3,834.41 | 16,971.12 | 10,400.82 | 15,263.52 |
| EXPENDITURE | | | | | | |
| 4 | a. (Increase)/Decrease in Stocks of | | | | | |
| | WIP & Finished/Traded Goods | (226.84) | (76.34) | (115.00) | (112.93) | (276.73) |
| | b. Consumption of raw materials | 2,294.89 | 1,113.78 | 5,378.80 | 2,927.68 | 4,126.62 |
| | c. Purchase of traded goods | 822.53 | 846.45 | 2,768.83 | 2,038.98 | 4,009.14 |
| | d. Employees Cost | 699.87 | 437.22 | 1,972.54 | 1,186.36 | 1,617.31 |
| | e. Depreciation/Amortisation | 134.84 | 80.00 | 416.81 | 236.46 | 306.82 |
| | f. Other Expenditure | 1,459.86 | 1,008.01 | 4,089.78 | 2,855.09 | 3,530.30 |
| | g. Total | 5,185.13 | 3,409.12 | 14,511.76 | 9,131.64 | 13,313.46 |
| 5 | Interest (Net) | 237.91 | 98.27 | 851.51 | 292.30 | 415.93 |
| 6 | Exceptional items | 280.51 | - | 280.51 | - | - |
| 7 | Profit (+)/Loss(-) from ordinary activity before tax (3)-(4+5+6) | 728.39 | 327.02 | 1,888.36 | 976.88 | 1,534.13 |
| 8 | Tax Expenses | | | | | |
| | - Current Tax | 79.43 | 47.00 | 211.61 | 120.00 | 170.65 |
| | - MAT Credit Entitlement | (79.43) | (47.00) | (211.61) | (120.00) | (170.00) |
| | - Deferred Tax | - | - | - | - | (586.65) |
| | - Fringe Benefit Tax | 6.50 | 12.37 | 20.70 | 25.07 | 30.76 |
| | - Tax of Earlier Years | - | - | - | - | 6.74 |
| | Total | 6.50 | 12.37 | 20.70 | 25.07 | (548.50) |
| 9 | Net Profit from ordinary activity after Tax (7-8) | 721.89 | 314.65 | 1,867.66 | 951.80 | 2,082.64 |
| 10 | Extra ordinary items (Net of Tax Expenses) | - | - | - | - | - |
| 11 | Net Profit for the period (9-10) | 721.89 | 314.65 | 1,867.67 | 951.80 | 2,082.64 |
| 12 | Paid up Equity Share Capital | 1,377.97 | 1,274.74 | 1,377.97 | 1,274.74 | 1,274.74 |
| | Face value of the Equity Share | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| 13 | Share Capital Suspense | 78.56 | 56.26 | 78.56 | 56.26 | 56.26 |
| 14 | Reserves excluding Revaluation reserve as per balance sheet of previous accounting year . | | | | | 8,970 |
| 15 | Earning Per Share (EPS) | | | | | |
| | a) Basic weighted EPS before extraordinary items (Not Annualised) | 5.05 | 2.81 | 13.07 | 8.24 | 15.65 |
| | b) Basic weighted EPS after extraordinary items (Not Annualised) | 5.05 | 2.81 | 13.07 | 8.24 | 15.65 |
| 16 | Public Shareholdings | | | | | |
| | - Number of Shares | 7,482,665 | 7,055,135 | 7,482,665 | 7,055,135 | 7,055,135 |
| | - Percentage of Shareholding | 54.30 | 55.35 | 54.30 | 55.35 | 55.35 |

Notes :-

- The Company has only one segment of activity namely "Pharmaceuticals".
- The above financial results have been reviewed by the Audit Committee and have been taken on record at the meeting of the Board of Directors of the Company held on 30/01/ 2008 .
- The Company had issued 1% Unsecured Foreign Currency Convertible Bonds of Euro 15 Million in two tranches namely Foreign Currency Convertible A Bonds (A Bonds) of Euro 8 Million, fully paid-up and Foreign Currency Convertible B Bonds (B Bonds) of Euro 7 Million, 10% paid-up, vide its Offering Circular dated 25/04/2007. The Company has received on 18/12/2007, the balance 90% unpaid amount of B Bonds i.e. Euro 6.30 Million. The B Bonds have been subscribed by Deutsche Bank & have a conversion price of Rs. 175 /- per equity share.
- During the quarter the Company has allotted 1,98,407 Equity Shares of Rs. 10/- each at a premium of Rs. 128.43 per Equity Share, upon conversion of 48 bonds of Foreign Currency Convertible A Bonds.
- Pursuant to the scheme of arrangement the company has allotted 58,199 OFCDs and 2,42,499 NCDs to the secured creditors of erstwhile The Pharmaceutical Products of India Ltd.(PPIL) on 06/12/2007
- The Company is in the process of ascertaining the final impact of Accounting Standard (Revised)15 "Employee Benefits" and will account for the same at the year end.
- The market price of the equity shares of the Company being less than the exercise price in respect of various outstanding options to subscribe to equity shares, the aforesaid options are considered to be anti dilutive.
- There were no investors complaints pending at the beginning of and the end of the quarter. During the last quarter the Company had received 25 complaints and the same were resolved.
- 7,85,557 Equity shares are to be allotted to the shareholders of DOCL which has merged with the Company w.e.f 01/04/2007 .
- Previous period figures have been recast to include those of PPIL which merged w.e.f. 01/04/2006

Place : Mumbai
Date : 30th Jan 2008

K CHANDRAN
WHOLE-TIME DIRECTOR

WANBURY LIMITED
CONSOLIDATED UNAUDITED FINANCIAL HIGHLIGHTS
FOR THE QUARTER ENDED 31ST DECEMBER 2007

| Particulars | For the Quarter ended 31-12-2007 (Unaudited) | For the Quarter ended 31-12-06 (Unaudited) | For the Period ended 31-12-2007 (Unaudited) | For the Period ended 31-12-2006 (Unaudited) |
|---|---|---|--|--|
| Turnover & other Income | 9,377.30 | 7,241.45 | 27,285.10 | 13,807.86 |
| EBIDTA | 1,349.86 | 1,102.46 | 5,312.50 | 2,102.80 |
| NET PROFIT AFTER TAX | 838.45 | 467.87 | 2,596.96 | 1,105.02 |
| EPS | 6.08 | 3.67 | 18.85 | 8.67 |
| The above financial highlights includes the financials of the subsidiary, Wanbury Holdings B.V. (Netharland) and Cantabria Pharma S.L.(Spain) | | | | |